Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q1 2023 · 10-Q
Revenue$2.78M$2.78M— vs Q1 2022 Net Income-$80.10M-$80.10MN/M vs Q1 2022 EPS Diluted-$1.31-$1.31N/M vs Q1 2022 Operating Income-$76,265,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
Free Cash Flowderived-$80,426,000N/M Margins · derivedOperating margin-2742.4%
Net margin-2880.3%
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end